Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Accounts Payables (2020 - 2025)

Historic Accounts Payables for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $6.4 million.

  • TScan Therapeutics' Accounts Payables rose 7419.8% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 7419.8%. This contributed to the annual value of $4.3 million for FY2024, which is 8020.22% up from last year.
  • Latest data reveals that TScan Therapeutics reported Accounts Payables of $6.4 million as of Q3 2025, which was up 7419.8% from $4.5 million recorded in Q2 2025.
  • TScan Therapeutics' Accounts Payables' 5-year high stood at $6.4 million during Q3 2025, with a 5-year trough of $1.8 million in Q4 2021.
  • Its 5-year average for Accounts Payables is $3.5 million, with a median of $3.2 million in 2023.
  • In the last 5 years, TScan Therapeutics' Accounts Payables tumbled by 4660.88% in 2022 and then skyrocketed by 13391.43% in 2025.
  • Quarter analysis of 5 years shows TScan Therapeutics' Accounts Payables stood at $1.8 million in 2021, then surged by 64.99% to $2.9 million in 2022, then fell by 18.48% to $2.4 million in 2023, then skyrocketed by 80.2% to $4.3 million in 2024, then soared by 48.5% to $6.4 million in 2025.
  • Its Accounts Payables was $6.4 million in Q3 2025, compared to $4.5 million in Q2 2025 and $5.0 million in Q1 2025.